HC Wainwright Weighs in on Apellis Pharmaceuticals, Inc.’s FY2025 Earnings (NASDAQ:APLS)

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Equities researchers at HC Wainwright boosted their FY2025 earnings per share (EPS) estimates for shares of Apellis Pharmaceuticals in a note issued to investors on Wednesday, May 8th. HC Wainwright analyst D. Tsao now expects that the company will earn $0.24 per share for the year, up from their prior estimate of $0.23. HC Wainwright currently has a “Buy” rating and a $92.00 target price on the stock. The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.27) per share. HC Wainwright also issued estimates for Apellis Pharmaceuticals’ FY2026 earnings at $2.64 EPS and FY2028 earnings at $6.77 EPS.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its earnings results on Tuesday, May 7th. The company reported ($0.54) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.54). The firm had revenue of $172.33 million during the quarter, compared to analyst estimates of $163.37 million. Apellis Pharmaceuticals had a negative net margin of 133.34% and a negative return on equity of 178.60%. Apellis Pharmaceuticals’s revenue was up 284.3% on a year-over-year basis. During the same period in the previous year, the business posted ($1.56) EPS.

APLS has been the subject of several other research reports. Robert W. Baird reaffirmed an “outperform” rating and set a $81.00 target price on shares of Apellis Pharmaceuticals in a research note on Tuesday, February 6th. Citigroup cut their target price on Apellis Pharmaceuticals from $67.00 to $60.00 and set a “buy” rating on the stock in a research report on Wednesday. Mizuho decreased their price target on Apellis Pharmaceuticals from $60.00 to $52.00 and set a “neutral” rating for the company in a research report on Monday, April 29th. Wedbush cut their price objective on Apellis Pharmaceuticals from $67.00 to $57.00 and set a “neutral” rating on the stock in a report on Wednesday, April 17th. Finally, Jefferies Financial Group upgraded shares of Apellis Pharmaceuticals from a “hold” rating to a “buy” rating and raised their target price for the stock from $68.00 to $80.00 in a report on Monday, February 5th. Three investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $76.67.

Apellis Pharmaceuticals Price Performance

APLS stock traded down $0.35 during trading on Friday, hitting $42.17. The company had a trading volume of 62,883 shares, compared to its average volume of 1,557,182. The business has a 50 day moving average of $53.91 and a 200 day moving average of $57.32. The firm has a market capitalization of $5.11 billion, a price-to-earnings ratio of -12.29 and a beta of 0.97. Apellis Pharmaceuticals has a fifty-two week low of $19.83 and a fifty-two week high of $94.75. The company has a current ratio of 3.10, a quick ratio of 2.50 and a debt-to-equity ratio of 0.48.

Insider Activity at Apellis Pharmaceuticals

In other news, CEO Cedric Francois sold 3,962 shares of the stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $67.77, for a total transaction of $268,504.74. Following the transaction, the chief executive officer now owns 313,662 shares of the company’s stock, valued at approximately $21,256,873.74. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Apellis Pharmaceuticals news, CEO Cedric Francois sold 3,962 shares of the company’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $67.77, for a total transaction of $268,504.74. Following the completion of the sale, the chief executive officer now directly owns 313,662 shares in the company, valued at $21,256,873.74. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Timothy Eugene Sullivan sold 1,431 shares of the firm’s stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $67.77, for a total value of $96,978.87. Following the completion of the sale, the chief financial officer now directly owns 93,338 shares in the company, valued at approximately $6,325,516.26. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 455,334 shares of company stock valued at $26,511,351. 7.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Apellis Pharmaceuticals

Hedge funds have recently bought and sold shares of the stock. Jennison Associates LLC grew its position in Apellis Pharmaceuticals by 79.8% during the third quarter. Jennison Associates LLC now owns 3,542,209 shares of the company’s stock worth $134,746,000 after buying an additional 1,571,606 shares in the last quarter. Assenagon Asset Management S.A. raised its stake in shares of Apellis Pharmaceuticals by 109.6% in the fourth quarter. Assenagon Asset Management S.A. now owns 2,145,004 shares of the company’s stock valued at $128,400,000 after purchasing an additional 1,121,497 shares in the last quarter. Norges Bank bought a new position in Apellis Pharmaceuticals in the fourth quarter worth $56,640,000. Price T Rowe Associates Inc. MD boosted its stake in Apellis Pharmaceuticals by 38.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,460,339 shares of the company’s stock worth $147,277,000 after buying an additional 677,098 shares in the last quarter. Finally, Polar Capital Holdings Plc raised its stake in shares of Apellis Pharmaceuticals by 126.6% in the 3rd quarter. Polar Capital Holdings Plc now owns 1,053,875 shares of the company’s stock valued at $40,089,000 after buying an additional 588,875 shares in the last quarter. 96.29% of the stock is owned by institutional investors.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).